CureVac is implementing our software immediately and secures its SAP systems with the SAST SUITE. We are very pleased about the assignment and future cooperation in the area of SAP Security & Authorizations.
Curevac N.V. is a publicly listed biopharmaceutical company based in the Netherlands, specialising in the development of a completely new class of drugs based on the messenger RNA (mRNA). The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases.
CureVac has pioneered the potential of mRNA to treat diseases and produce vaccines. Based on this mRNA technology, they are currently developing a vaccine against the coronavirus.
CureVac has been listed on the New York Nasdaq since August 2020. The company is headquartered in Tübingen (DE) and has more than 500 employees at its sites in Tübingen, Frankfurt and Boston, USA.
Press release from Nov. 23, 2020 (in German): CureVac und WACKER unterzeichnen Vertrag zur Produktion des COVID-19-Impfstoffkandidaten CVnCoV – gemeinsame Pressemitteilung
About SAST SOLUTIONS by AKQUINET
In addition to our proprietary software suite, our SAST SOLUTIONS also offer consulting and managed services. As a strong and competent partner, we provide holistic SAP Security & Compliance solutions. More than 200 customers and over 3.5 million SAP users worldwide now rely on our expertise to protect their SAP systems from hacker attacks, espionage and data theft.